Diversity, Equity and Inclusion:
As members of PhRMA, we believe improving human life means celebrating human diversity
Commitment to DE&I
We are committed to a fair, equitable and non-discriminatory workplace where there are meaningful platforms for dialogue and progress. This starts from the top – our managers are expected to act as role models for our values every day. We are committed to creating a gender-balanced and inclusive workplace, and to see change, we have to start with our people.
Takeda’s Center for Health Equity and Patient Affairs
We recently launched our R&D Center for Health Equity and Patient Affairs (CHEPA). CHEPA will operate as a center of excellence, positioning Takeda as a leader in health equity and patient centricity to create a more inclusive ecosystem and strengthen trust and reputation with patients and other key external stakeholders around the world. It will ensure that DE&I considerations inform our planning for clinical trials and other research and development activities.
Talent Acquisition, Development & Retention
Takeda has and will continue to strengthen our talent acquisition processes with an enhanced focus on diversity, equity and inclusion. There are a number of initiatives underway:
• Implementation of Bias reducing tool (in final stages with technology vendors)
• Roll out of DE&I and Behavioral Based interview training
• Implementation enterprise-wide Candidate Relationship Management (CRM) tool connected with Applicant Tracking System (ATS) to create inclusive talent communities
Environmental Sustainability:
As members of PhRMA, we believe a healthy environment is essential for improving human life
Merck Accelerates Climate Goals; Announces Carbon Neutrality in Operations by 2025
In April 2021, Merck announced ambitious goals to achieve carbon neutrality across its operations by 2025 (Scopes 1 & 2 emissions) and a 30% reduction in its value chain emissions by 2030 (Scope 3 emissions).1
These goals are aligned with science and build on Merck’s long-standing focus on preventing the worst impacts of climate change and supporting the global effort to achieve the Paris Agreement goals by reducing demand for energy and minimizing greenhouse gas (GHG) emissions.
Our Commitment to Environmental Sustainability for a Brighter Future
Our Commitment to Environmental Sustainability for a Brighter Future
By 2025, we commit to reducing GHG emissions in our operations by 40% from FY2016 levels. We will cut Scope 3 emissions by 15% based on FY2018 levels.
By 2024, we will help 67% of our suppliers to establish their own science-based emissions targets.
We are committed to working to achieve net-zero GHG emissions in our operations before 2035. By 2040, we are committed to reaching net-zero for our entire value chain, including currently estimated scope 3 GHG emissions.
By 2025, we commit to reducing GHG emissions in our operations by 40% from FY2016 levels. We will cut Scope 3 emissions by 15% based on FY2018 levels.
By 2024, we will help 67% of our suppliers to establish their own science-based emissions targets.
We are committed to working to achieve net-zero GHG emissions in our operations before 2035. By 2040, we are committed to reaching net-zero for our entire value chain, including currently estimated scope 3 GHG emissions.
Sustainability by Design
Our Sustainability by Design program aims to minimize our environmental footprint by incorporating sustainability principles during every stage of product development. The activities involve R&D, Drug Products & Processing and Packaging and Devices. They are designed to minimize the environmental impact of all future products throughout their life cycle.
Access & Affordability:
As members of PhRMA, we believe that living our mission of improving human life relies on broad access to medicines
Patient Assistance Programs (PAPS)
PAPS support patients who have difficulty accessing medicines to obtain our innovative and life-saving treatments. PAPs are a cornerstone of Takeda’s Access to Medicines strategy to increase sustainable access to our medicines for complex and rare diseases and build sustainable capacity across the patient journey, addressing accessibility barriers. Our Access to Medicines programs operate in the healthcare systems of 54 countries and territories around the world. These programs have provided treatment to more than 70,000 patients with life-threatening diseases, enabled the screening of more than 46,000 patients, and supported the training of more than 800 health care professionals and community healthcare workers in evolving healthcare systems. In the United States and Europe, we have PAPs to help support patients who have difficulty accessing medicines, particularly in rare and complex diseases.
Sponsorship
Alkermes is proud to be part of the broader healthcare community supporting those with addiction, serious mental illness and cancer. In 2020 and 2021, we sponsored non-profit organizations such as the National Alliance on Mental Illness (NAMI), the Partnership to End Addiction and the American Cancer Society while continuing to bring awareness to programs and initiatives of other organizations that work to improve the lives of persons affected by mental illness, substance use disorder and cancer.
Improving Access to Qualified Health Care in Rural West Africa
Working with 12 private schools in the three countries, the program will increase the number of qualified, trained nurses who can serve rural communities facing a critical shortage of health workers in these countries - all as part of the effort to ensure that everyone everywhere has access to health care.